➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
AstraZeneca
Colorcon
McKinsey
Dow

Last Updated: December 3, 2020

DrugPatentWatch Database Preview

Litigation Details for ELI LILLY AND COMPANY v. ACCORD HEALTHCARE, INC., USA (S.D. Ind. 2012)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in ELI LILLY AND COMPANY v. ACCORD HEALTHCARE, INC., USA
The small molecule drugs covered by the patent cited in this case are   Start Trial and   Start Trial .

Details for ELI LILLY AND COMPANY v. ACCORD HEALTHCARE, INC., USA (S.D. Ind. 2012)

Date Filed Document No. Description Snippet Link To Document
2012-01-20 1 Exhibit A-Patent US 7,772,209 B2 AND COMPANY. (Attachments: # 1 Exhibit A-Patent US 7,772,209 B2)(DH) (Entered: 01/23/2012) 20 January…2012 21 April 2017 1:12-cv-00086 830 Patent None District Court, S.D. Indiana External link to document
2012-05-16 28 types of cancer. U.S. Patent No. 7,772,209 (“the ’209 patent”) covers a method of administering…the ’209 patent. The filing of the ANDA constitutes infringement of the ’209 patent. The use… requirements for patentability and enforceability of the patent. By way of Counterclaims…Statement. This is a Hatch-Waxman patent infringement action, arising out of Accord’s filing… vitamin B12. Lilly is the assignee of the ’209 patent. External link to document
2017-04-21 87 , 19, and 21 of Lilly’s U.S. Patent No. 7,772,209 (“the ’209 patent”), and those claims have not been…than the latest date of expiration of the ’209 patent, including any period of pediatric exclusivity.…2012 21 April 2017 1:12-cv-00086 830 Patent None District Court, S.D. Indiana External link to document
2017-08-11 97 August 10, 2010, U.S. Patent No. 7,772,209 (“Patent ’209”) was issued to Lilly. Patent ’209 covers the method… Eli Lilly and Company’s United States Patent No. 7,772,209. Case No. 1:10-cv-1373-TWP-DKL, ECF 420…claims of [Patent ’209]; d. in the event that the asserted claims of [Patent ’209] patent are invalidated… to the Patent Trial and Appeal Board (“PTAB”) seeking inter partes review (“IPR”) of Patent ’209. Apotex…the Court that Patent ’209 is invalid. Additionally, even if the PTAB ruled that Patent ’209 was invalid External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Harvard Business School
Merck
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.